CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Inc CRMD has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the FDA. 

  • In parallel, the Company's third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter issued by the FDA concurrently with the CRL.
  • In March last year, the FDA issued a CRL noting concerns at the third-party manufacturing facility.
  • DefenCath is being developed as a catheter lock solution with an initial indication of use to reduce catheter-related bloodstream infections in patients with renal failure receiving chronic hemodialysis via a central venous catheter. 
  • The FDA has 30 days to review the submission for completeness to accept for filing and provide guidance on the review timeline.
  • Dr. Phoebe Mounts, General Counsel and Head of Technical Operations at CorMedix noted, "as CorMedix has previously announced, FDA has stated that satisfactory resolution of the deficiencies may require a preapproval inspection of the manufacturing facility."
  • Price Action: CRMD shares are up 20.90% at $4.86 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!